NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties.
View Full Paper
Ask AI
Bookmark
Share
Why the study?
Does S-nitroso-BSA act as a stable nitric oxide carrier with EDRF-like properties in a canine model?
Population
16 mongrel dogs of either sex weighing 20-26 kg
Comparison
S-nitroso-BSA administered via intravenous… vs Nitroglycerin, S-nitroso-cysteine, sodium…
Design
Preclinical, The order of drug administration was chosen at random in order to…
Authors
Discussion
Loading...
Member takes
Implication
Supports development of stable NO carriers for sustained vasodilation; leaves open clinical efficacy and safety in humans.
Structured PICO
Does S-nitroso-BSA act as a stable nitric oxide carrier with EDRF-like properties in a canine model?
P
Population
16 mongrel dogs of either sex weighing 20-26 kg
I
Intervention
S-nitroso-BSA (S-NO-BSA) administered via intravenous bolus, intravenous infusion, or intracoronary infusion
C
Comparator
Nitroglycerin, S-nitroso-cysteine, sodium nitroprusside, acetylcholine, and controls (BSA, NaNO2, L-cysteine, vehicle)
O
Outcome
Changes in mean arterial pressure, coronary blood flow, coronary artery diameter, bleeding time, and ex vivo platelet aggregationsurrogate
S-nitroso-BSA acts as a stable, biologically active nitric oxide carrier with potent, prolonged EDRF-like vasorelaxant and antiplatelet properties in vivo.
Cite This Study
Keaney et al. (1993) studied this question.
View Full Paper
Ask AI
Bookmark
Share